Reference pricing for pharmaceuticals: Is the Australia-United States Free Trade Agreement affecting Australia's Pharmaceutical Benefits Scheme?

Medical Journal of Australia

Volumn 187, Issue 4, 2007, Pages 240-242

  Faunce, Thomas A ^a  

^a The Australian National University   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG;

ARTICLE; AUSTRALIA; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG LEGISLATION; DRUG SAFETY; FUNDING; HEALTH CARE POLICY; PATENT; PHARMACY; UNITED STATES; COMMERCIAL PHENOMENA; HEALTH INSURANCE; HUMAN; INTERNATIONAL COOPERATION; ORGANIZATION AND MANAGEMENT; REIMBURSEMENT; REVIEW;

AUSTRALIA; COMMERCE; DRUG COSTS; HEALTH CARE REFORM; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; INTERNATIONALITY; REIMBURSEMENT MECHANISMS; UNITED STATES;

EID: 34848870043     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2007.tb01209.x     Document Type: Article

References (20)

1. Australian Government Department of Health and Ageing. National Medicines Policy. 2000. http://www.health.gov.au/internet/wcms/ Publishing.nsf/Content/nmp-objectives-policy.htm/$FILE/nmp2000.pdf (accessed Apr 2007).
2. Australian Government Department of Foreign Affairs and Trade. Australia-United States Free Trade Agreement. 2004. http://www.dfat.gov.au/trade/negotiations/us.html (accessed Mar 2007).
3. Australian Government Department of Health and Ageing. PBAC outcomes and public summary documents. http://www.health.gov.au/internet/wcms/ publishing.nsf/Content/pbac-outcomes-and-public-summary-documents (accessed Jun 2007).
4. Australian Government. Independent Review (PBS). http://www.independentreviewpbs.gov.au (accessed Jun 2007).
5. US Department of Health and Human Services. Australia-US Medicines Working Group holds first meeting. 2006. http://www.globalhealth.gov/ Australia_meds_011406.shtml (accessed Jan 2006; no longer available).
6. Australian Government Department of Health and Ageing. PBS Latest News. PBS cost recovery consultations are happening. http://www.pbs.gov.au/ html/healthpro/news/article?id=NEWS-2007-04-18-Cost_Recovery.xml (accessed Jun 2007).
7. Ray WA, Stein CM. Reform of drug regulation - beyond an independent drug-safety board. N Engl J Med 2006; 354: 194-201.
8. Lopert R (Medical Adviser, Pharmaceutical Benefits Branch, Department of Health and Ageing). Senate Select Committee on the Free Trade Agreement between Australia and the United States of America. Canberra: Official Committee Hansard, Monday 21 June 2004: FTA24. http://www.aph.gov.au/ Senate/committee/freetrade_ctte/hearings/ (accessed Feb 2007).
9. Harvey KJ, Faunce TA, Lokuge B, Drahos P. Will the Australia-United States Free Trade Agreement undermine the Pharmaceutical Benefits Scheme? Med J Aust 2004; 181: 256-259.
10. Faunce T, Doran E, Henry D, et al. Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy. Global Health 2005; 1: 15.
11. Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (US) 21 USC conference agreement House Report 108-391 Title XI - Access to Pharmaceuticals. Bipartisan Trade Promotion Authority Act of 2002 (US), 107-210 § 2102 (b) (8) (D).
12. US Department of Commerce International Trade Administration. Pharmaceutical price controls in OECD countries: implications for US consumers, pricing, research and development, and innovation. Washington, DC: ITA, 2004. http://www.ita.doc.gov/td/chemicals/ drugpricing-study.pdf (accessed Apr 2006).
13. Scherer P (Head Health Division). Delegates to the OECD Group on Health. Pharmaceutical pricing policy [letter]. Organisation for Economic Co-Operation and Development. 20 Sep 2005.
14. Deady S (Special Negotiator, Office of Trade Negotiations, Department of Foreign Affairs and Trade). Senate Select Committee on the Free Trade Agreement between Australia and the United States of America. Canberra: Official Committee Hansard, Monday 21 June 2004: FTA 12, FTA 16. http://www.aph.gov.au/Senate/committee/freetrade_ctte/hearings/ (accessed Feb 2007).
15. Vaile M (Deputy Prime Minister and Minister for Trade). Joint press conference at the office of the United States Trade Representative, Washington, DC. 7 Mar 2006. http://www.trademinister.gov.au/transcripts/ 2006/060306_us_jt.html (accessed Jun 2007).
16. Laming A. Let's overhaul the Pharmaceutical Benefits Scheme. The Australian 2006; 10 Jan: 10.
17. Australian Government Department of Health and Ageing. AUSFTA - Medicines Working Group - 2007 meeting statement. http://www.health.gov.au/internet/wcms/publishing.nsf/Content/ health-ausfta-statement-2007 (accessed Jun 2007).
18. Office of the US Trade Representative. Proposed United States-Korea FTA texts. Chapter Five. Pharmaceuticals and medical devices. http://www.ustr.gov/Trade_Agreements/Bilateral/Republic_of_Korea_FTA/ Draft_Text/Section_Index.html (accessed May 2007).
19. Faunce TA, Lexchin J. Linkage pharmaceutical evergreening in Canada and Australia. Aust New Zealand Health Policy 2007; 4: 8. http://www.anzhealthpolicy.com/content/4/1/8 (accessed Jun 2007).
20. Delaat W (Chairman of Medicines Australia). National Press Club speech 2005. Pharma in Focus 2005; 8 Aug. http://www.pharmainfocus.com.au/news.asp?newsid=825 (accessed Jun 2007).